140 related articles for article (PubMed ID: 10552942)
1. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.
Salven P; Teerenhovi L; Joensuu H
Blood; 1999 Nov; 94(10):3334-9. PubMed ID: 10552942
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.
Salven P; Orpana A; Teerenhovi L; Joensuu H
Blood; 2000 Dec; 96(12):3712-8. PubMed ID: 11090051
[TBL] [Abstract][Full Text] [Related]
3. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.
Ruotsalainen T; Joensuu H; Mattson K; Salven P
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1492-5. PubMed ID: 12433733
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.
Rujirojindakul P; Lekhakula A
ScientificWorldJournal; 2012; 2012():215231. PubMed ID: 22629121
[TBL] [Abstract][Full Text] [Related]
5. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
Wróbel T; Poreba M; Mazur G; Poreba R; Pyszel A; Beck B; Steinmetz-Beck A; Andrzejak R; Kuliczkowski K
Neoplasma; 2006; 53(3):253-8. PubMed ID: 16652197
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
Bono P; Teerenhovi L; Joensuu H
Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
[TBL] [Abstract][Full Text] [Related]
7. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.
Salven P; Teerenhovi L; Joensuu H
Blood; 1997 Oct; 90(8):3167-72. PubMed ID: 9376599
[TBL] [Abstract][Full Text] [Related]
8. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of proangiogenic cytokines in children with lymphomas.
Mizia-Malarz A; Sobol G; Janowska J; Wos H; Zahorska-Markiewicz B
Pediatr Blood Cancer; 2009 Dec; 53(7):1195-9. PubMed ID: 19621434
[TBL] [Abstract][Full Text] [Related]
10. VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma.
Wróbel T; Mazur G; Dzietczenia J; Gębura K; Kuliczkowski K; Bogunia-Kubik K
Biomed Res Int; 2013; 2013():159813. PubMed ID: 23998120
[TBL] [Abstract][Full Text] [Related]
11. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis.
Ueno K; Inoue Y; Kawaguchi T; Hosoe S; Kawahara M
Lung Cancer; 2001; 31(2-3):213-9. PubMed ID: 11165400
[TBL] [Abstract][Full Text] [Related]
12. Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma.
Pazgal I; Zimra Y; Tzabar C; Okon E; Rabizadeh E; Shaklai M; Bairey O
Br J Cancer; 2002 Jun; 86(11):1770-5. PubMed ID: 12087465
[TBL] [Abstract][Full Text] [Related]
13. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.
Blay JY; Burdin N; Rousset F; Lenoir G; Biron P; Philip T; Banchereau J; Favrot MC
Blood; 1993 Oct; 82(7):2169-74. PubMed ID: 8400266
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
Niitsu N; Okabe-Kado J; Kasukabe T; Yamamoto-Yamaguchi Y; Umeda M; Honma Y
Blood; 1999 Nov; 94(10):3541-50. PubMed ID: 10552965
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):316-21. PubMed ID: 12607599
[TBL] [Abstract][Full Text] [Related]
16. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
17. Non-Hodgkin's lymphomas: immunologic prognostic studies.
Hadzi-Pecova L; Petrusevska G; Stojanovic A
Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
[TBL] [Abstract][Full Text] [Related]
18. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma.
Poon RT; Ng IO; Lau C; Yu WC; Fan ST; Wong J
Am J Surg; 2001 Sep; 182(3):298-304. PubMed ID: 11587697
[TBL] [Abstract][Full Text] [Related]
19. High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma.
Fang S; Repo H; Joensuu H; Orpana A; Salven P
Eur J Cancer; 2011 Jul; 47(11):1708-16. PubMed ID: 21439815
[TBL] [Abstract][Full Text] [Related]
20. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.
Horstmann M; Merseburger AS; von der Heyde E; Serth J; Wegener G; Mengel M; Feil G; Hennenlotter J; Nagele U; Anastasiadis A; Bokemeyer C; Stenzl A; Kuczyk M
J Cancer Res Clin Oncol; 2005 Nov; 131(11):715-22. PubMed ID: 16080018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
